Serum N-glycomics for non-invasive detection of significant liver pathology across clinical phases of treatment-naive chronic hepatitis B.

ABSTRACT:

Background

Early identification of significant liver pathology is crucial for timely antiviral intervention in individuals with chronic hepatitis B (CHB) infection. Current non-invasive methods show limited accuracy in detecting occult liver damage, particularly in those with normal ALT. This study evaluated serum N-glycan profiles for diagnosing significant liver pathology in treatment-naïve CHB patients across clinical phases.

Methods

This cross-sectional study analyzed 626 treatment-naïve CHB patients confirmed by liver biopsy, classified according to 2025 EASL guidelines. Serum N-glycan profiles were determined using DNA sequencer-assisted fluorophore-assisted carbohydrate electrophoresis. Significant liver pathology was defined as inflammation grade ≥ G2 and/or fibrosis

SUBMITTER: Li X 

PROVIDER: S-EPMC12905847 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature